Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD2423 · 4 trials · 4 indications
Monocyte count in BAL post-LPS challenge (Day 11)
Last Observation Carried Forward (LOCF). Twice daily, the participants rated their Average Pain intensity during the past 12 hours on an Numerical Rating Scale (NRS) scale 0-10. 0= No pain, 10= Worst pain imaginable.
Number of all participants with clinically significant changes in laboratory variables, except monocyte, assessed at all the listed time points
Number of participants with clinically significant changes in vital signs assessed at all the listed time points
Number of participants with clinically significant changes in ECG variables assessed at all the listed time points
Number of participants with clinically significant changes in physical examination assessed at all the listed time points
Monocyte count in peripheral blood at baseline (Pre-dose, Day 1)
Monocyte count in peripheral blood at end of treatment (4 weeks)
Monocyte count in peripheral blood at follow-up (Week 5; 1 week after end of treatment)
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Oral treatment |
| 2 | PLACEBO_COMPARATOR | Oral treatment |
| AZD2423, 20mg | EXPERIMENTAL | - |
| AZD2423, 150 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | Tablet to match the 20 mg and 50 mg AZD2423 active tablet |
| AZD2423 | EXPERIMENTAL | AZD2423 Oral Treatment for 28 days |
| AZD2423, 20 mg | EXPERIMENTAL | Tablets, 20 mg once daily in the morning. |
| Name | Type | Description |
|---|---|---|
| AZD2423 | DRUG | 100mg Oral dose od |
| AZD2423 Placebo | DRUG | Oral dose od |
| Placebo | DRUG | Placebo |
| Placebo to AZD2423 | DRUG | Oral treatment once daily for 28 days |
Inclusion Criteria: * Only women of non-child bearing potential are included in the study i.e. women who are permanently or surgically sterilised or post menopausal. * ≥ 40 years of age at Visit 1 * Clinical diagnosis of COPD (GOLD stage 1) * FEV1 ≥ 80% of the predicted normal post-bronchodilator a...
AZD2423 is an investigational small molecule developed by AstraZeneca PLC. It has been studied in Phase 2 clinical trials for chronic obstructive pulmonary disease (COPD) and for nerve pain, including neuropathic pain. It is a CCR2 antagonist and is not an approved medicine.
AZD2423 has been studied in clinical trials for chronic obstructive pulmonary disease (COPD) and for nerve pain, including neuropathic pain such as painful diabetic polyneuropathy and posttraumatic neuralgia. It is investigational and has not been approved for any use.
AZD2423 targets CCR2, a chemokine receptor. It acts as a CCR2 antagonist, meaning it blocks this receptor rather than activating it. This target class is the basis for its study in inflammatory airway disease such as COPD and in neuropathic pain conditions.
AZD2423 is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca sponsored the Phase 2 studies of the compound in COPD and in nerve pain, including neuropathic pain.
AZD2423 is in Phase 2 development. It is investigational and has not been approved by the FDA or any other regulator. All of its recorded Phase 2 trials are completed, and no trials are currently active.
Four completed Phase 2 trials are recorded for AZD2423: NCT01215279 and NCT01153321 in COPD, NCT01201317 in painful diabetic polyneuropathy, and NCT01200524 in posttraumatic neuralgia. All were randomized, double-blind, and placebo-controlled, with enrollment ranging from 63 to 134 participants.
Yes. AZD2423 is also referred to as Part 2 - AZD2423, Part 2- AZD2423, Part 3 - AZD2423, and Part 3- AZD2423. These are alternate labels for the same AstraZeneca CCR2 antagonist compound, so searches using any of these names refer to AZD2423.